Venetoclax for paediatric acute myeloid leukaemia: a step forward

Modifiable Risk Factors and Major Cardiac Events Among Adult Survivors of Childhood Cancer

Armstrong, G. T., Oeffinger, K. C., Chen, Y., Kawashima, T. I., Yasui, Y., Leisenring, W. M., Stovall, M., Chow, E. J., Sklar, C. A., Mulrooney, D. A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.3205 · Cited by 737

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

Dinardo, C. D., Pratz, K. W., Letai, A. G., Jonas, B. A., Wei, A. H., Thirman, M. J., Arellano, M. L., Frattini, M. G., Kantarjian, H. M., Popovic, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30010-x · Cited by 723

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

Dinardo, C. D., Tiong, I. S., Quaglieri, A., MacRaild, S., Loghavi, S., Brown, F. C., Thijssen, R., Pomilio, G., Ivey, A., Salmon, J. M., et al. (2020) · Blood · doi:10.1182/blood.2019003988 · Cited by 681

Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia

Zwaan, C. M., Kolb, E. A., Reinhardt, D., Abrahamsson, J., Adachi, S., Aplenc, R., de Bont, E. S. J. M., Moerloose, B. D., Dworzak, M. N., Gibson, B. E. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.8289 · Cited by 394

Improved Outcome in Pediatric Relapsed Acute Myeloid Leukemia: Results of a Randomized Trial on Liposomal Daunorubicin by the International BFM Study Group

Kaspers, G. J. L., Zimmermann, M., Reinhardt, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.7384 · Cited by 238

Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study

Karol, S. E., Alexander, T., Budhraja, A., Pounds, S. B., Canavera, K. E., Wang, L., Wolf, J., Klco, J. M., Mead, P. E., Gupta, S. D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30060-7 · Cited by 165

Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): A therapeutic advances in childhood leukemia (TACL) consortium study

Gorman, M. F., Ji, L., Ko, R. H., et al. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22612 · Cited by 112

Occurrence of Treatment-Related Cardiotoxicity and Its Impact on Outcomes Among Children Treated in the AAML0531 Clinical Trial: A Report From the Children’s Oncology Group

Getz, K., Sung, L., Ky, B., Gerbing, R. B., Leger, K. J., Leahy, A. B., Sack, L., Woods, W. G., Alonzo, T. A., Gamis, A. S., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00313 · Cited by 102

IDA‐FLAG (idarubicin, fludarabine, cytarabine, G‐CSF), an effective remission‐induction therapy for poor‐prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial

Fleischhack, Hasan, Graf, N. M., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00836.x · Cited by 98

AAML 1421, a phase I/II study of CPX-351 followed by fludarabine, cytarabine, and G-CSF (FLAG) for children with relapsed acute myeloid leukemia (AML): A Report from the Children’s Oncology Group.

Cooper, T. M., Absalon, M. J., Alonzo, T. A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.10003 · Cited by 11

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396

Durable Response with Venetoclax in Combination with Decitabine or Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML)

Dinardo, C. D., Pratz, K. W., Potluri, J., et al. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.07.050 · Cited by 1

CLO22-037: Tumor Lysis Syndrome and Infectious Complications During Induction With Venetoclax Combined With Azacitidine or Decitabine in Patients With Acute Myeloid Leukemia

Arora, S., Zainaldin, C., Bathini, S., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.7292

Abstract 4037: In vitro cytotoxicity of CPX-351 plus venetoclax compared with hypomethylating agents or cytarabine plus venetoclax

Gupta, A., Humphreys, R. C., Hanson, D. J., et al. (2020) · Cancer Research · doi:10.1158/1538-7445.am2020-4037 · Cited by 10

Venetoclax Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia

Hernandez, J. V., Condom, M., Pomares, H., et al. (2021) · Blood · doi:10.1182/blood-2021-153100 · Cited by 1

P568: REAL-LIFE EXPERIENCE OF TREATMENT REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA PATIENTS WITH VENETOCLAX COMBINATION THERAPY

Marin, H. P., Hernandez, J. V., Esteve, M. C., et al. (2022) · HemaSphere · doi:10.1097/01.hs9.0000845160.95755.c5

Age-Adjusted Schedules of Venetoclax and Hypomethylating Agents to Treat Extremely Elderly Patients with Acute Myeloid Leukemia

Lee, A. M., Goodman, A. M., & Mangan, J. K. (2022) · Case Reports in Hematology · doi:10.1155/2022/2802680 · Cited by 2

Epigenetic Regulation of OCTN1‐mediated Cytarabine Transport in Acute Myeloid Leukemia

Anderson, J. T., Buelow, D. R., Guttke, C. D., et al. (2019) · The FASEB Journal · doi:10.1096/fasebj.2019.33.1_supplement.675.2

POSA49 Projecting the Long-Term Benefits of Venetoclax Combination Therapies for Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy: An Assessment of Net Health Benefit

Schuh, A., Pratz, K. W., Lachaîne, J., et al. (2022) · Value in Health · doi:10.1016/j.jval.2021.11.194

Efficacy of the combination of venetoclax and hypomethylating agents in the treatment of patients with primary, relapsed and/or refractory acute myeloid leukemia

Usikova, E. V., Kaplanov, K. D., Vorobyev, V. I., Lobanova, T. I., Ul'yanova, M. A., Kisilichina, D. G., Kobzev, Y. N., Шихбабаева, Д. И., Vinogradova, O., & Ptushkin, V. V. (2022) · Bulletin of the Medical Institute REAVIZ (REHABILITATION DOCTOR AND HEALTH) · doi:10.20340/vmi-rvz.2022.6.clin.5

The Goldilocks Dilemma in AML: Too Young and Fit, but Not Young and Fit Enough

Martin, E. C. S., Zhang, T. Y., & Mannis, G. N. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.03.011 · Cited by 1